Cristin-resultat-ID: 2015924
Sist endret: 7. april 2022, 13:33
NVI-rapporteringsår: 2022
Resultat
Vitenskapelig artikkel
2022

The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort

Bidragsytere:
  • Heidi Øyen Flemmen
  • Cecilia Smith Simonsen
  • Line Broch
  • Cathrine Brunborg
  • Pål Berg-Hansen
  • Stine Marit Moen
  • mfl.

Tidsskrift

Multiple Sclerosis and Related Disorders
ISSN 2211-0348
e-ISSN 2211-0356
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2022
Publisert online: 2022

Importkilder

Scopus-ID: 2-s2.0-85127199652

Beskrivelse Beskrivelse

Tittel

The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort

Sammendrag

Objective: Several studies report an impact of socioeconomic factors on access to disease modifying treatment (DMT) in multiple sclerosis (MS), with a trend of less access to more deprived persons. We investigated the impact of socioeconomic status (SES) on access to treatment in a well-defined Norwegian MS cohort. Methods: This is a study of a population-based Norwegian MS cohort. We collected detailed information on disease development, progression, and DMT administered. Socioeconomic data was obtained from Statistics Norway and a questionnaire. Results: We included 1314 persons with relapsing remitting MS at the prevalence date 01/01/2018. The population ever treated with DMTs is younger at onset, has shorter time from onset to diagnosis and lower expanded disability status score (EDSS) at diagnosis. The persons with MS (pwMS) with the highest levels of education, and those who are married are more likely to be ever treated with DMT. In the subgroup treated with a high efficacy DMT as a first drug, the pwMS are younger at prevalence date (39.9 years (SD 12.1)) compared with those who are not treated with a high efficacy DMT as first drug (43.8 years (SD 10.3)). The subgroup treated with a high efficacy DMT as a first drug has a 0.5 point higher EDSS at diagnosis compared to those not treated with a high efficacy DMT as a first drug. The level of education, household income and marital status are inversely related to access to high efficacy DMT as a first drug. None of the above differences persist when analyzing the subgroup diagnosed within the last six years (2012-2017). Conclusions: Since 2012, the pwMS in this Norwegian cohort are treated equally with DMT in terms of different measures of socioeconomic position.

Bidragsytere

Heidi Øyen Flemmen

  • Tilknyttet:
    Forfatter
    ved Medisinsk klinikk ved Sykehuset Telemark HF
  • Tilknyttet:
    Forfatter
    ved Institutt for klinisk medisin ved Universitetet i Oslo

Cecilia Smith Simonsen

  • Tilknyttet:
    Forfatter
    ved Drammen sykehus ved Vestre Viken HF
  • Tilknyttet:
    Forfatter
    ved Institutt for klinisk medisin ved Universitetet i Oslo

Line Broch

  • Tilknyttet:
    Forfatter
    ved Institutt for klinisk medisin ved Universitetet i Oslo
  • Tilknyttet:
    Forfatter
    ved Drammen sykehus ved Vestre Viken HF

Cathrine Brunborg

  • Tilknyttet:
    Forfatter
    ved Biostatistikk, epidemiologi og helseøkonomi (OSS) ved Oslo universitetssykehus HF

Pål Berg-Hansen

  • Tilknyttet:
    Forfatter
    ved Nevrologisk avdeling ved Oslo universitetssykehus HF
1 - 5 av 8 | Neste | Siste »